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spectrometry (QqQ-MS) was developed for direct quantitative analysis of benzodiazepines
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(BDZs) and their metabolites, as well as BDZ analogs (zopiclone, zolpidem, and zaleplon) in
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diluted human urine. A perfluorophenyl column packed with sub-2-mm particles and a C8
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precolumn were applied to accomplish RRLC analysis with symmetric peak shapes. Urine
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samples were diluted 10-fold with Milli-Q water prior to autoinjection for direct quantification of 34 target analytes with negligible matrix effect. Gradient elution and dynamic

Keywords:

multiple reaction monitoring were used for simultaneous quantitation of 34 BDZs, me-

Benzodiazepines

tabolites, and BDZ analogs. Good recovery was obtained in the range of 80.2e98.5% and the

Clinical diagnosis

limit of detection ranged from 0.01 ng/mL to 0.5 ng/mL for all 34 target analytes in spiked

Human urine

urine. Moreover, good precision and accuracy were obtained for quantitative determina-

Rapid resolution liquid chromatog-

tion in diluted urine samples by the proposed RRLC/QqQ-MS method for intra-day/

raphy tandem mass spectrometry

inter-day assays in the ranges of 0.1e8.8%/0.1e8.9% and 91.2e106.1%/89.6e104.6%,

Quantitative screening

respectively. The applicability of this newly developed RRLC/QqQ-MS method was
demonstrated by quantitative determination of BDZs, metabolites, and BDZ analogs in
various clinical urine samples.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.

1.

Introduction

Benzodiazepines (BDZs) and their analogs, such as zopiclone,
zolpidem and zaleplon, have been used as prescribed

medications for treating anxiety, insomnia, or muscle spasm
after they became commercially available since the 1960s
[1,2]. Although BDZs were considered to have low toxicity, the
potential of addiction or dependence has still received much
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attention from time to time [2,3]. In addition, abuse of BDZs
and some related substances was found to be associated with
suicide or drug-facilitated sexual assault. In many cases, the
drug-facilitated sexual assault victims might not report the
event and receive medical attention until several hours or
days after the incident. Therefore, a rapid and sensitive
analytical method became desirable to determine quantitatively the trace residual BDZs and/or metabolites in biological
fluids, such as urine, and provide valuable information for
clinical diagnosis as well as forensic applications [4e8].
Several publications have reported the quantitation of
BDZs and related substances in biological samples including
hair, blood, and urine by various analytical techniques.
Several research groups reported the use of immunoassays for
determining BDZs in either hair or urine samples, however,
cross-reactions were frequently observed and other chromatographic methods were usually required to determine
quantitatively individual BDZs [9,10]. Miller et al [9] reported
that crossreactivity of various BDZs ranged from 8% to 143%
for microplate enzyme-linked immunosorbent assay directed
towards oxazepam, due to similar structures or common
crossreacting epitopes of BDZs and metabolites. The
commonly used chromatographic methods for quantifying
BDZs in biological samples included gas chromatography (GC)
coupled to mass spectrometry (MS) [6,10,11] and liquid chromatography (LC) with UV [12e14] or MS detection [4,7,15e22].
In most GCeMS methods, derivatization and sample pretreatment process, such as liquideliquid extraction (LLE),
were often required for simultaneous quantification of BDZs
in biological samples [6,10]. Recently, ultra-performance
liquid chromatography (UPLC) or rapid resolution liquid
chromatography (RRLC) coupled to MS was used for simultaneous quantitation of multiple BDZ-related substances in
biological samples [5,15,20]. Compared with conventional
high-performance
liquid
chromatography
(HPLC)eMS
methods, UPLCeMS or RRLCeMS offers the advantages of
rapid analysis and enhanced sensitivity for quantitative
determination [5,15,20,21]. Although LCeMS methods were
considered to be suitable for quantifying BDZs in biological
samples without derivatization, sample pretreatment procedures such as LLE [21,22], solid phase extraction (SPE)
[4,7,15e17], or molecularly imprinted SPE [18,19] were generally involved in order to reduce the matrix effect and to achieve sensitive detection. For instance, Verplaetse et al [15]
claimed that the limit of detection (LOD) of 29 BDZs and
BDZ-like hypnotics in urine ranged from 0.02 ng/mL to 0.2 ng/
mL using SPE prior to UPLCetandem MS analysis. Ariffin and
colleagues [18] used molecularly imprinted SPE for extracting
BDZs and metabolites from hair samples and reported the
LODs and limits of quantitation (LOQs) in the range of
0.03e0.78 ng/mL and 0.06e1.32 ng/mL, respectively.
In this study, a RRLC/triple quadrupole MS (QqQ-MS) system was established for direct quantitation of BDZs, metabolites, and BDZ analogs (zopiclone, zolpidem, and zaleplon) in
dilute human urine without tedious sample pretreatment
procedures. The experimental conditions for MS detection
and RRLC analysis were optimized prior to evaluating the
proposed RRLC/QqQ-MS method for quantitative screening of
BDZ metabolites and BDZ analogs. The following experiments,
including dynamic multiple reaction monitoring (dMRM)
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parameters for QqQ-MS detection, the effect of formic acid in
mobile phase, the use of precolumn prior to the RRLC separation, as well as minimizing the matrix effect by dilution and
postcolumn addition, were performed to achieve the optimal
conditions for analyzing 34 BDZs and related substances. The
quantitative performance of the proposed RRLC/QqQ-MS
method was validated by obtaining the linear range, precision, and accuracy, as well as the LOD and LOQ of individual
analytes under the optimal conditions. Clinical urine samples
were diluted with Milli-Q water and then directly quantified
by RRLC/QqQ-MS to demonstrate the applicability of the proposed RRLC/QqQ-MS method for clinical applications.

2.

Methods

2.1.

Materials and reagents

Internal standards (ISTD-1: zolpidem-d6 and ISTD-2: prazepam-d5), 7-aminonitrazepam, 7-aminoclonazepam, 4hydroxynordiazepam, 7-aminoflunitrazepam, zopiclone, bromazepam, chlordiazepoxide, zolpidem, a-hydroxymidazolam,
oxazepam, a-hydroxyalprazolam, a-hydroxytriazolam, trazodone, nitrazepam, lorazepam, zaleplon, N-desmethylflunitrazepam, 2-hydroxyethylflurazepam, nordiazepam,
estazolam, midazolam, clonazepam, desalkylflurazepam,
temazepam, flurazepam, lormetazepam, nimetazepam, flunitrazepam, clobazam, alprazolam, triazolam, brotizolam,
diazepam, and prazepam were purchased from Cerilliant
Corp. (Austin, TX, USA). HPLC-grade methanol and acetonitrile
were obtained from Mallinckrodt Baker, Inc. (Paris, KY, USA).
Formic acid (98e100%) and ammonium formate were purchased from Riedel-de Haen (Seelze, Germany). Deionized
water was produced from a Milli-Q Integral 5 water purification
system (Millipore, Bedford, MA, USA). Drug-free urine samples
were collected from voluntary healthy adults for the study.

2.2.

Instrumentation and LC conditions

Chromatographic separation was carried on an Agilent 1200
Series RRLC system (Agilent, Waldbronn, Germany), including
an online degasser, a binary pump, an autosampler, equipped
with a Zorbax SB-C8 pre-column (2.1 mm  30 mm, 3.5 mm;
Agilent) and a Hypersil GOLD perfluorophenyl (PFP) column
(2.1 mm  100 mm, 1.9 mm; Thermo Scientific, Waltham, MA,
USA) in an Agilent Thermostatted Column Compartment (set
at 40  C). Gradient elution was used during the separation
process. The mobile phase consisted of two solvents: solvent
A was Milli-Q water containing 0.1% formic acid and 1mM
ammonium formate; and solvent B was acetronitrile containing 0.1% formic acid and 1mM ammonium formate.
Starting from 10% B, the mobile phase was changed to 20% B in
3 minutes, then to 40% B in a further 5 minutes, and to 70% B in
an additional 4 minutes. Afterwards, the mobile phase was
immediately raised to 99% B for 1.5 minutes and the LC column was re-equilibrated for 3.5 minutes using 10% B. The flow
rate was set at 0.3 mL/min.
An Agilent 6410 Triple quad LC/MS mass spectrometer was
used for QqQ-MS detection under the positive mode with
electrospray ionization source at a spray voltage of 4000 V.
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Heated N2 gas (10 L/min at 350  C) served as drying gas to
evaporate solvent from the ionization chamber. System control, data acquisition, and data processing for RRLC/QqQ-MS
analysis were performed using Agilent Mass Hunter Workstation (version B.02.01) software. dMRM (time window: retention
time  1 min) [23,24] was utilized for QqQ-MS measurement.

2.3.

Urine sample preparation

One milliliter of urine sample containing two ISTDs (2 ng/mL
each) was diluted 10-fold with Milli-Q water. About 1 mL of
clean supernatant was transferred to the autosampler sample
vial. Then, 20 mL of the pretreated sample solution was autoinjected for RRLC/QqQ-MS analysis.

2.4.

Validation process

The following experiments were performed to validate the
proposed method for quantitative analysis of BDZs, metabolites, and analogs in human urine. A calibration curve, peak
area ratios (analyte/ISTD) versus concentration, was

established for each analyte to evaluate the linearity by the
proposed RRLC/QqQ-MS method for quantitative screening.
Calibration standards (0.1 ng/mL, 0.5 ng/mL, 1 ng/mL, 5 ng/mL,
10 ng/mL, 50 ng/mL, 100 ng/mL, 250 ng/mL, and 500 ng/mL)
containing two ISTDs (2 ng/mL each) were prepared by spiking
different amounts of analytes into drug-free urine to make the
standard mixtures with desired concentrations. The spiked
urine standards were then diluted 10 times with Milli-Q water
prior to RRLC/QqQ-MS analysis. Measurements of each standard solution were carried out in triplicate and the LOD and
LOQ were determined using the single-to-noise ratio of 3 and
the lowest concentration in the linear range, respectively. The
precision and accuracy, including intra-day and inter-day
experiments, were evaluated using three different concentrations of spiked urine samples. Quantitation of all target
analytes was determined by the peak area ratios (Aanal/AISTD),
where Aanal is the peak areas of individual analytes and AISTD
is the peak areas of the corresponding ISTD (zolpidem-d6 or
prazepam-d5). As shown in Table 1, analytes 1e16 and 17e34
were determined using zolpidem-d6 and prazepam-d5 as the
corresponding ISTD, respectively.

Table 1 e MRM parameters for RRLC/QqQ-MS analysis under positive mode.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

7-Aminonitrazepam
7-Aminoclonazepam
4-Hydroxynordiazepam
7-aminoflunitrazepam
Zopiclone
Bromazepam
Chlordiazepoxide
Zolpidem
Zolpidem-d6 (ISTD-1)
a-Hydroxymidazolam
Oxazepam
a-Hydroxyalprazolam
a-Hydroxytriazolam
Trazodone
Nitrazepam
Lorazepam
Zaleplon
N-Desmethylflunitrazepam
2-Hydroxyethylflurazepam
Nordiazepam
Estazolam
Midazolam
Clonazepam
Desalkyflurazepam
Temazepam
Flurazepam
Lormetazepam
Nimetazepam
Flunitrazepam
Clobazam
Alprazolam
Triazolam
Brotizolam
Diazepam
Prazepam
Prazepam-d5 (ISTD-2)

[MþH]þ

Monitored ions

Fragmentor (V)

Collision energy (V)

252
286
287
284
389
316
300
308
314
342
287
325
359
372
282
321
306
300
333
271
295
326
316
289
301
388
335
296
314
301
309
343
393
285
325
330

121a/94/74
250/222/121a
165a/140/77
135a/93/77
245a/217/112
208/182a/154
282a/227/165
263/235a/65
263/235a/65
324a/203/168
269/241a/77
297a/216/205
331a/239/176
176a/148/78
236a/207/180
303/275a/229
264/236a/64
254a/225/198
211/140/109a
165/140a/77
267a/205/151
291a/249/209
270a/214/151
226/140a/77
255a/193/177
317/315a/134
289a/177/75
250a/221/165
268a/239/183
259a/224/77
281a/205/151
315/308a/239
314a/279/210
193a/154/89
271a/165/140
276a/165/140

144
144
144
144
92
144
92
144
144
144
92
144
144
144
144
92
144
144
144
144
144
144
144
144
92
144
92
144
144
92
144
144
144
144
144
144

24/40/64
16/24/28
28/28/72
28/60/80
12/36/72
40/36/76
20/20/56
24/36/80
24/36/80
20/24/44
8/20/68
24/44/48
28/28/48
24/36/64
24/36/40
12/21/36
20/24/80
24/36/40
36/44/28
28/28/60
20/44/72
28/40/36
24/40/76
28/32/72
20/36/40
16/20/60
20/44/80
24/36/56
24/36/64
16/32/60
24/44/76
28/24/44
20/28/44
32/28/80
20/40/40
20/40/40

MRM ¼ multiple reaction monitoring; QqQ-MS ¼ triple quadrupole mass spectrometry; RRLC ¼ rapid resolution liquid chromatography.
a
Quantitative ion.
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3.

Results and discussion

3.1.

Optimization of RRLC/QqQ-MS conditions

Using the condition mentioned in Urine sample preparation and
Table 1, the same precursor ions ([MþH]þ) or transitions of
target analytes/ISTDs reported in various publications
[4,15e17,20,22,25] were detected. Therefore, the [MþH]þ ion
was chosen as the precursor ion for QqQ-MS measurements.
The characteristic fragment ions for identification and quantitative determination of each analytical component were
summarized in Table 1 to conduct further experiments.
Due to the complex chemical structures of BDZs [5], a PFP
column was utilized for analyzing BDZs and related substances in the present study. Previous publications showed
that this type of packing material was suitable for halogenated
compounds as well as analytes with a phenyl ring and/or a
fused ring system [26,27]; however, using only a PFP column
resulted in asymmetric peak shapes for some analytes as
shown in Fig. 1A. The peak shapes were greatly improved, as
shown in Fig. 1B, whereas an additional C8 column was
applied prior to the PFP column.
Furthermore, improved LC resolution and decreased MS
sensitivity were observed by the increasing amounts of formic
acid (0.1%, 0.2%, and 0.5%) in the mobile phase. Therefore,
0.1% formic acid was added to the mobile phase to achieve
better LC resolution with a small (w10%) decrease in sensitivity. The representative chromatograms of spiked urine
(10 ng/mL each) are shown in Fig. 2. Under optimized UPLC
elution conditions, the analysis of 34 BDZs could be completed
within 13 minutes. As a result, this UPLC method can analyze
more BDZs in less time compared to the reported LC methods
[9,18].

Fig. 1 e Peak shape of target analytes (10 ng/mL,
eastazolam as the example) in spiked Milli-Q water
without (A) or with (B) the use of C8 precolumn prior to the
perfluorophenyl column.
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Fig. 2 e Representative chromatograms of benzodiazepinespiked (10 ng/mL) urine sample. Sample was diluted 10fold by Milli-Q water prior to rapid resolution liquid
chromatography/triple quadrupole mass spectrometry
analysis. The peak identification is shown in Table 1.

3.2.

Matrix effect in human urine

Diluted urine samples were used for direct analysis by RRLC/
QqQ-MS to avoid the laborious sample pretreatment procedures such as LLE and SPE. BDZ-spiked (10 ng/mL each)
urine samples diluted five-fold, 10-fold, and 20-fold using
Milli-Q water were utilized for evaluating the effect of dilution
factor on the recovery/yield. The average recoveries (n ¼ 3) of
the total 34 analytes in five-fold, 10-fold, and 20-fold diluted
urines were 74.7%, 86.7%, and 90.0%, respectively. In five-fold
diluted urine samples, there were 25 analytes with recoveries
<80% and 11 analytes with recoveries <70%. All analytes in
both 10-fold and 20-fold diluted urine samples had recoveries
in the ranges of 80.2e98.5% and 80.9e98.9%, respectively.
Although higher recoveries were found in 20-fold dilute urine
samples, we used 10-fold diluted urine for the subsequent
experiments to achieve better sensitivity in quantitative
measurement.
To study further the matrix effect during a complete
chromatographic run, the postcolumn infusion [28,29] of a
standard mixture in Milli-Q water was used to monitor the
matrix interference in RRLC/QqQ-MS analysis of urine samples. Using an auxiliary syringe pump, a standard mixture
(50 ng/mL each) was delivered and joined (through a T-junction) into the analytical effluent before the electrospray for MS
detection. As shown in Fig. 3, a noticeable matrix effect caused
by the endogenous components in diluted urine sample was
observed in high aqueous conditions (analysis time 1e2 minutes), whereas little influence on MS signals was found after
2 minutes throughout the rest of the LC analysis. The use of
diluted urine was confirmed suitable for direct analysis of
BDZs, metabolites, and BDZ analogs by RRLC/QqQ-MS, with
negligible matrix effect.
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3.3.

Fig. 3 e Matrix effect of diluted urine (10-fold dilution) on
mass spectrometry signals using postcolumn infusion.
Infusion profiles for a standard mixture (50 ng/mL each)
after injection of (A) Milli-Q water and (B) dilute urine.

Quantitative performance

The validation of applying RRLC/QqQ-MS for direct quantitative determination of BDZs, metabolites, and BDZ analogs was
achieved by examining the linearity, LOD, LOQ, as well as
precision and accuracy using spiked urine samples under
optimal conditions. The merits of quantitative measurement
(linearity, LOD and LOQ) of individual analytes are summarized in Table 2. In the total 34 target analytes, more than twothirds of them had a linear range around three orders of
magnitude and only two analytes (trazodone and flurazepam)
less than two orders. The LODs of all analytes were determined to be 0.5 ng/mL and half of them had LODs in the
range of 0.01e0.05 ng/mL. The precision and accuracy of the
proposed method were also investigated and the results are
summarized in Table 3. Both intra-day and inter-day experiments were performed at three concentration levels. The
ranges of precision for intra-day and inter-day assays were
0.1e8.8% and 0.1e8.9%, respectively. The corresponding accuracy ranges were 91.2e106.1% and 89.6e104.6% for intraday and inter-day experiments, respectively. Based on these

Table 2 e Retention time, linear range, LOD, and LOQ of benzodiazepines and metabolites by rapid resolution liquid
chromatography/ triple quadrupole mass spectrometry analysis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Retention
time (min)

Linear
range (ng/mL)

LOD (ng/mL)

LOQ (ng/mL)

3.28
5.38
6.83
6.94
7.05
8.01
8.23
8.79
9.62
9.63
9.67
9.71
9.81
9.89
9.94
9.96
10.00
10.13
10.20
10.37
10.37
10.43
10.57
10.73
10.94
11.04
11.06
11.09
11.09
11.13
11.24
11.45
11.56
12.93

0.1e500.0
0.1e500.0
0.1e250.0
0.1e500.0
1.0e250.0
1.0e500.0
0.1e500.0
5.0e500.0
0.1e500.0
0.5e500.0
1.0e500.0
5.0e500.0
10.0e500.0
0.5e500.0
1.0e500.0
0.1e500.0
0.5e500.0
0.5e500.0
0.5e500.0
0.1e500.0
5.0e500.0
0.5e500.0
0.5e500.0
0.5e500.0
0.5e5.0
0.5e100.0
0.1e500.0
0.1e500.0
0.1e500.0
0.1e500.0
0.1e500.0
0.5e500.0
0.1e500.0
0.5e500.0

0.025
0.05
0.05
0.05
0.25
0.50
0.05
0.01
0.05
0.25
0.25
0.50
0.025
0.10
0.50
0.10
0.25
0.25
0.25
0.01
0.10
0.25
0.10
0.10
0.025
0.25
0.05
0.05
0.05
0.05
0.05
0.10
0.05
0.025

0.1
0.1
0.1
0.1
1.0
1.0
0.1
5.0
0.1
0.5
1.0
5.0
10.0
0.5
1.0
0.1
0.5
0.5
0.5
0.1
5.0
0.5
0.5
0.5
0.5
0.5
0.1
0.1
0.1
0.1
0.1
0.5
0.1
0.5

7-Aminonitrazepam
7-Aminoclonazepam
4-Hydroxynordiazepam
7-Aminoflunitrazepam
Zopiclone
Bromazepam
Chlordiazepoxide
Zolpidem
a-Hydroxymidazolam
Oxazepam
a-Hydroxyalprazolam
a-Hydroxytriazolam
Trazodone
Nitrazepam
Lorazepam
Zaleplon
N-Desmethylflunitrazepam
2-Hydroxyethylflurazepam
Nordiazepam
Estazolam
Midazolam
Clonazepam
Desalkyflurazepam
Temazepam
Flurazepam
Lormetazepam
Nimetazepam
Flunitrazepam
Clobazam
Alprazolam
Triazolam
Brotizolam
Diazepam
Prazepam

LOD ¼ limit of detection; LOQ ¼ limit of quantitation.
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Table 3 e Precision and accuracy at three concentration levels for the quantitative determination of 34 target analytes.
Concentration levela

7-Aminonitrazepam
7-Aminoclonazepam
4-Hydroxynordiazepam
7-aminoflunitrazepam
Zopiclone
Bromazepam
Chlordiazepoxide
Zolpidem
a-Hydroxymidazolam
Oxazepam
a-Hydroxyalprazolam
a-Hydroxytriazolam
Trazodone
Nitrazepam
Lorazepam
Zaleplon
N-Desmethylflunitrazepam
2-Hydroxyethylflurazepam
Nordiazepam
Estazolam
Midazolam
Clonazepam
Desalkylflurazepam
Temazepam
Flurazepam
Lormetazepam
Nimetazepam
Flunitrazepam
Clobazam
Alprazolam
Triazolam
Brotizolam
Diazepam
Prazepam

Intra-day (n ¼ 3)

Inter-day (n ¼ 3)

(ng/mL)

Precision (RSD, %)

Accuracy (%)

Precision (RSD, %)

Accuracy (%)

0.5/10.0/250.0
0.5/10.0/250.0
0.5/10.0/100.0
0.5/10.0/250.0
5.0/10.0/100.0
5.0/10.0/250.0
0.5/10.0/250.0
10.0/50.0/250.0
0.5/10.0/250.0
1.0/10.0/250.0
5.0/10.0/250.0
10.0/50.0/250.0
50.0/100.0/250.0
1.0/10.0/250.0
5.0//10.0/250.0
0.5/10.0/250.0
1.0/10.0/250.0
1.0/10.0/250.0
1.0/10.0/250.0
0.5/10.0/250.0
10.0/100.0/250.0
1.0/10.0/250.0
1.0/10.0/250.0
1.0/10.0/250.0
0.5/1.0/5.0
1.0/10.0/50.0
0.5/10.0/250.0
0.5/10.0/250.0
0.5/10.0/250.0
0.5/10.0/250.0
0.5/10.0/250.0
1.0/10.0/250.0
0.5/10.0/250.0
1.0/10.0/250.0

1.0/0.3/0.4
2.1/1.9/2.2
4.0/3.1/6.8
0.7/2.2/1.8
1.5/6.4/8.5
2.9/1.2/0.3
1.5/1.9/1.8
0.7/3.1/2.3
3.7/0.3/2.4
0.3/2.6/2.1
6.3/1.9/1.2
3.8/7.7/0.9
0.9/1.7/0.6
4.7/0.8/6.7
7.1/6.3/2.2
2.2/1.3/2.7
3.7/3.2/0.6
3.5/1.1/1.0
7.3/2.2/0.3
6.4/1.7/1.0
0.3/3.5/0.2
8.6/0.7/1.6
5.9/3.6/0.7
5.6/1.0/0.3
0.7/2.5/5.2
8.8/1.3/3.4
3.7/1.9/2.5
1.3/1.2/1.2
2.7/1.1/0.1
7.0/0.3/1.1
2.1/0.4/0.7
6.5/2.0/2.5
0.3/2.3/1.3
0.2/0.9/0.8

100.1/99.9/100.1
99.5/100.7/100.1
105.0/100.4/100.1
98.4/99.6/101.3
100.5/105.4/99.0
98.1/99.5/100.4
94.3/100.9/100.3
91.2.101.2/101.0
101.3/99.7/99.1
98.5/98.5/102.1
100.5/100.3/98.7
100.5/98.9/92.4
104.4/100.7/98.3
98.9/100.0/100.2
99.0/96.2/102.8
100.5/98.8/100.2
99.6/99.3/100.3
99.7/99.9/99.5
100.5/100.3/98.9
99.1/100.6/101.5
94.9/102.4/99.9
106.1/98.6/98.3
96.8/100.4/101.0
100.6/99.5/100.6
99.7/100.7/99.6
98.8/102.1/102.2
101.2/99.3/101.4
96.8/100.4/100.2
96.8/101.2/100.8
101.2/99.3/99.2
97.8/100.7/100.5
103.3/99.4/99.7
104.3/98.7/98.9
99.4/99.2/100.2

2.1/1.6/2.7
2.4/0.5/1.8
7.9/0.7/1.9
3.9/2.3/1.9
1.6/2.5/0.4
0.5/0.4/0.7
2.3/2.1/0.7
1.8/2.1/2.7
2.4/0.1/0.1
4.2/2.4/0.5
0.9/0.6/0.4
5.1/1.5/4.7
3.7/4.8/4.6
1.8/0.9/0.2
0.9/2.0/1.0
6.8/2.4/4.2
4.5/0.8/0.9
2.7/0.7/0.5
1.1/1.3/0.8
1.6/1.7/0.4
2.1/3.1/3.9
8.9/1.9/1.7
2.0/0.7/1.1
0.6/4.0/2.8
0.8/3.9/2.3
1.7/1.4/2.6
5.2/1.0/0.4
3.9/0.6/0.8
4.2/2.1/2.6
3.8/0.7/3.6
2.7/1.6/1.2
2.6/1.0/2.4
5.6/1.6/0.6
0.7/2.0/0.3

100.9/101.3/97.8
98.4/101.0/100.1
97.6/101.2/101.6
97.7/97.1/102.3
99.7/102.5/99.1
98.6/100.1/100.6
95.6/100.1/101.1
89.6/102.7/103.5
102.3/99.5/99.1
98.8/96.9/102.6
101.4/99.8/99.1
98.2/100.6/97.5
100.4/98.1/101.9
97.9/100.1/100.1
98.1/97.5/103.4
96.3/96.4/104.6
99.7/100.2/99.8
97.9/100.7/99.8
99.4/100.6/99.2
97.4/98.9/101.8
96.2/99.4/102.4
98.2/100.7/99.7
99.0/100.2/100.6
100.1/95.8/103.1
99.0/103.7/98.0
100.1/101.0/99.6
96.7/100.4/101.0
95.2/100.8/100.9
95.1/99.7/102.4
97.7/98.8/102.1
97.2/99.3/101.2
100.4/98.3/102.0
99.6/99.9/99.7
99.1/100.3/100.0

RSD ¼ relative standard deviation.
a
Three concentration levels (low/medium/high) were chosen depending on the linear range of individual analyte.

results, this RRLC/QqQ-MS method was verified to be suitable
for direct quantitative screening of BDZs, metabolites, and
BDZ analogs in diluted human urine. In addition, these results
are comparable with other reported LC-MS/MS methods for
analyzing BDZs and related substances in human urine. For
instance, Marin et al [4] reported an LOD of 10 ng/mL for
13 BDZs, whereas Verplaetse’s group [15] claimed that the
LODs ranged from 0.02 ng/mL to 0.2 ng/mL for 29 BDZs and
BDZ-like hypnotics in urine. Ishida et al [5] reported an LOD of
0.2e8.0 ng/mL for 43 BDZs and their metabolites by UPLC-MS/
MS. However, all these studies involved a time-consuming
pretreatment process that could take up to several hours
prior to LC-MS/MS analysis.

3.4.
Application: Quantitative screening of multiple
BDZ-related substances in human urine
Several clinical urine samples from a local hospital were
analyzed by the proposed RRLC/QqQ-MS method. Fig. 4 shows
the representative chromatograms of a drug-free urine sample and a clinical urine sample. In this clinical sample, three

compounds were identified and quantified based on the three
MRM transitions of individual analytes shown in Table 1.
Compared with the urine blank and the BDZ-spiked samples, the unidentified peak shown in Fig. 4A could be the
matrix components from the individual. Table 4 summarizes
the identified compounds with their corresponding concentrations in the urine samples. For example, 7aminoclonazepam, the major metabolite of clonazepam [2],
was found in three clinical urine samples with concentrations
ranging from 1.3 ng/mL to 79.3 ng/mL. Combined with personal background information as well as medication history,
the ingested amounts, or the time periods of drug intake
might be resolved and offer useful information for clinical
diagnosis or giving proper medical treatments to patients.
In conclusion, we developed a rapid and sensitive RRLC/
QqQ-MS method using a sub-2-mm packed PFP column for
quantitative analysis of BDZs, metabolites, and BDZ analogs in
diluted human urine. In this newly developed assay, only a
minimal sample pretreatment procedure (dilution of urine
sample) was needed; however, no significant deterioration on
LC column performance was observed after >200 injections of
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determine quantitatively the 34 BDZs and related substances.
We have demonstrated a newly developed rapid RRLC/QqQ-MS
method with low LOD values as an alternative for highthroughput quantitative measurement of BDZs, metabolites,
and BDZ analogs in human urine for clinical applications.
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